This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Non-dihydropyridine calcium channel antagonists in rate control in atrial fibrillation (AF)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Non-dihydropyridine calcium channel antagonists in control of rate in atrial fibrillation (1)

Usual oral maintenance dose

verapamil

40 mg b.i.d. to 360 mg (ER) o.d.

diltiazem

60 mg t.i.d. to 360 mg (ER) o.d.

ER = extended release formulations

Reference:

  • (1) Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. European Heart Journal (2010) 31, 2369-2429.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.